KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Cash & Equivalents (2016 - 2026)

NovoCure's Cash & Equivalents history spans 13 years, with the latest figure at $87.5 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents fell 31.23% to $87.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $87.5 million, a 31.23% decrease, with the full-year FY2025 number at $93.5 million, down 42.88% from a year prior.
  • Cash & Equivalents hit $87.5 million in Q1 2026 for NovoCure, down from $93.5 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for NVCR hit a ceiling of $453.8 million in Q1 2024 and a floor of $87.5 million in Q1 2026.
  • Historically, Cash & Equivalents has averaged $201.4 million across 5 years, with a median of $164.8 million in 2024.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 144.01% in 2024 and later plummeted 71.95% in 2025.
  • Tracing NVCR's Cash & Equivalents over 5 years: stood at $115.3 million in 2022, then skyrocketed by 108.82% to $240.8 million in 2023, then crashed by 32.0% to $163.8 million in 2024, then crashed by 42.88% to $93.5 million in 2025, then fell by 6.44% to $87.5 million in 2026.
  • Business Quant data shows Cash & Equivalents for NVCR at $87.5 million in Q1 2026, $93.5 million in Q4 2025, and $342.1 million in Q3 2025.